13 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
. Given the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel
DRS/A
ed9whizgbmn8
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
neq3me8
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
xaveltnwie
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
u4bq5m 539d9jzxob416
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
4rr5 vl8b9zuf9jy
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
5f0sqz4c7cjtl
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
eysktcti6090w
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
cwqle z5t18vfq16r7z
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next